 In the present study, the investigators propose a Phase I randomized double-blind study designed to assess the feasibility and safety of autologous CD133 cells in patients referred for CABG who have significant regions of viable but non-revascularizable myocardium andor significant LV systolic dysfunction not likely to improve with conventional coronary revascularization. 